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Prognostic histological factors may contribute to determine 
the evolution of this neoplasia. Aim: To correlate p53 and 
Ki-67 immunohistochemical expression with age, histological 
degree, lymph node involvement and pathological staging 
in patients with laryngeal epidermoid carcinomas. Methods: 
We assessed thirty consecutive cases of laryngeal epidermoid 
carcinomas submitted to immunohistochemistry to check 
the expression of p53 e Ki-67 antibodies. Results: Mean 
age was of 56.2 years and the immunoexpression of the 
markers was observed in the group with more than 50 
years of age, especially that o the ki-67 antibody (p=0.032). 
There was no relation between p53 and Ki-67 with lymph 
node involvement. Ki-67 was expressed in 70% of the high 
histology level cases and in 80% in the low histology ones; 
while p53 was of 70% only in the high level cases. Pathology 
staging showed that in the group of advanced carcinomas, 
p53 expression was of 61.5%, while Ki-67 proved positive for 
the early cases (100%) and advanced (73.1%). Conclusion: 
There were no significant differences between p53 and Ki-
67 immunoexpression in laryngeal epidermoid carcinoma, 
except in the group of patients with more than 50 years of 
age, when Ki-67 expression was significantly higher.
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INTRODUCTION
Laryngeal cancer accounts for approximately 12,000 
new cases per year in the United States and for 2% of all 
cancer-related deaths1. Some 130,000 new cases of laryn-
geal cancer are recorded in the world, affecting predomi-
nantly males at a rate of 7:1. Laryngeal tumors are among 
the most frequent cases of head and neck cancer, as they 
account for approximately 25% of the malignant tumors 
involving this area. About 2/3 of these tumors appear in 
the glottis and 1/3 involve the supraglottal region.
Epidermoid carcinomas are the most common his-
tological type, including keratinizing (well-differentiated) 
and non-keratinizing tumors. They account for 2.2% of ma-
lignant neoplasms in men and 0.4% in women2,3. Laryngeal 
carcinomas may involve all three anatomical sites, namely 
the glottis, subglottis, and supraglottal region.
The following histological prognostic factors for la-
ryngeal carcinomas are considered: tumor site, histological 
type, histological grade, and lymph node status. Lymph 
node involvement is one of the most important prognostic 
factors for laryngeal carcinomas.
Cell growth suppressor genes and cell death regula-
tor genes are relevant variables in tumor evolution; among 
them is gene p534-6. Gene p53 is a proto-oncogene that 
regulates cell growth. It singles out cells with DNA altera-
tions, interrupts the growth cycle on stage G1, and places 
altered cells on G0. It then promotes cell repair to send 
the cell back to the cycle or, if that cannot be done, pro-
motes cell death. The correlation between p53 expression 
and prognosis for various types of cancer has been well 
demonstrated7. The immunohistochemical expression of 
p53 leads to increased protein expression or mutation.
Cell proliferation is also seen as a fundamental bio-
logic mechanism in oncogenesis8 and in the detection of 
cell growth fraction markers such as antibody Ki-67, used 
as a prognostic factor in a wide variety of tumors9-11.
Correlation between high proliferative activity and 
worse prognosis for laryngeal and head and neck tumors 
has shown, particularly for neoplasms invading structures 
located adjacently to the tumor’s site of origin4,5,8,9. This 
study aims to relate the immunohistochemical expression 
of gene p53 and antibody Ki-67 to established prognostic 
factors (age, histological grade, lymph node status, and 
disease staging) in patients with laryngeal epidermoid 
carcinoma.
MATERIALS AND METHOD
This study comprises a review of thirty consecu-
tive cases of laryngeal epidermoid carcinoma diagnosed 
at the Head and Neck Service at Hospital Luterano da 
Universidade Luterana do Brasil between January of 2004 
and September of 2006. All patients underwent laryngec-
tomy and neck clearance. Our sample includes all cases 
of epidermoid carcinoma, regardless of tumor location. 
The cases were examined by the Pathology Service using 
conventional hematoxylin-eosin staining techniques and 
were later sent to immunohistochemistry to check for ex-
pression of antibodies p53 and Ki-67. Next, patients were 
compared in terms of age, histological grade, lymph node 
involvement, and tumor staging.
Immunohistochemistry tests were done from tissue 
samples previously fixated in 10% formalin, embedded 
in paraffin blocks, manually sliced at 3 microns using 
a rotational microtome, and mounted in organosilane. 
Each slide also contained immunohistochemically active 
control tissue to avoid false negative results. Slides were 
prepared as follows:
a. Preparation of histology cuts;
b. Deparaffination and hydration;
c. Antigenic recovery through irradiation in micro-
wave oven;
d. Blocking endogenous peroxidase: slides were 
placed in a solution of 5% hydrogen peroxide and dis-
tilled water and then in a solution of 5% skim milk and 
phosphate buffer (PBS) for 40 minutes in a humid dark 
chamber; slides were then washed in water, distilled water, 
and placed in PBS for 5 minutes;
e. Incubation of primary antibody anti-Ki 67 and 
p53 (Dako);
f. Reaction of the avidin-biotin-streptavidin com-




Negative result was defined as absence of stained 
nuclei or immunosuppression under 10% in tumor cells 
for markers p53 and Ki-67. Positive results were defined as 
10% or more stained nuclei. This was based on criteria from 
our service, as there is no consensus in the literature as to 
the minimum thresholds to consider results as positive.
In terms of age, our patients were divided into two 
groups: (1) patients younger than 50 years (2) and patients 
50 and older.
In terms of lymph node involvement, patients were 
divided into two groups: (1) positive neck lymph nodes 
for metastasis (pN1, pN2) and (2) negative lymph nodes 
for metastasis (pN0).
In terms of histological grade, epidermoid carcino-
mas were divided into two groups: (1) low grade, or well 
differentiated - keratinizing (grade I); and (2) high grade, 
or moderate to little differentiation (grades II and III).
In terms of disease staging (pT) cases were divided 
into two groups, according to the TNM System from the 
Union Internationale Contre Cancer (UICC): (1) cancer with 
local involvement (including pT1) and (2) cancer involving 
neighboring structures (including pT2, pT3, and pT4).
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Statistical analysis was done using software pro-
gram SPSS release 15.0. The chi-square test was used to 
compare categorical variables. The combined association 
between Ki-67 and p53 tumor immune expression and 
other analyzed variables (age, gender, lymph node in-
volvement, histological grade, and disease staging [pT, 
pN]) was assessed through statistical analysis. Statistical 
significance was assigned when p<0.05.
This study was approved by the Research Ethics 
Committee at Universidade Luterana do Brasil under per-
mit 2006-192H.
RESULTS
This study included 30 patients (28 males and 2 fe-
males) histologically diagnosed with laryngeal epidermoid 
carcinoma. All subjects were submitted to total laryngec-
tomy combined with neck clearance.
The results from the comparisons done between 
the expression of antibodies p53 and Ki-67, and prog-
nostic factors (age, gender, lymph node involvement, 
histological grade, and disease staging) can be seen on 
Tables 1 and 2.
Patient age ranged between 21 and 80 years (mean 
56.2 years). In the group aged 50 and more, significantly 
higher levels of immune expression were seen for antibody 
Ki-67 (p = 0.032).
As for the other prognostic factors (lymph node 
involvement, histological grade, and disease staging), 
there was a trend towards increased p53 and Ki-67 im-
mune expression in cases of higher histological grade and 
advanced disease, but such difference failed to achieve 
statistical significance (p>0.05).
Table 1. Correlation between prognostic factors and the p53 gene expression in patients with laryngeal epidermoid carcinoma.
Prognostic factor Positive p53 Negative p53 p
< 50 years 2 (50%) 2 (50%) n.s.
> 50 years 16 (61,5%) 10 (38,5%) n.s.
Positive Lymph nodes 9 (60%) 6 (40%) n.s.
Negative lymph nodes 9 (60%) 6 (40%) n.s.
Low grade 4 (40%) 6 (60%) n.s.
High grade 14 (70%) 6 (30%) n.s.
T1 staging 2 (50%) 2 (50%) n.s.
T2 – T4 staging 16 (61,5%) 10 (38,5%) n.s.
Table  2. Correlation between prognostic factors and Ki-67 antibody expression in patients with SCC.
Prognostic factor Positive ki-67 Negative ki-67 p
< 50 years 2 (50%) 2 (50%) n.s.
> 50 years 21 (80,8%) 5 (19,2%) 0,032
Positive lymph nodes 11 (73,3%) 4 (26,7%) n.s.
Negative lymph nodes 12 (80%) 3 (20%) n.s.
Low grade 8 (80%) 2 (20%) n.s.
High grade 15 (75%) 5 (35%) n.s.
T1 staging 4 (100%) 0 (0%) n.s.
T2 – T4 staging 19 (73,1%) 7 (26,9%) n.s.
DISCUSSION
A lot has been found about prognostic markers for 
laryngeal carcinoma within the last few years. Nonethe-
less, reports of statistical correlations between p53 and 
Ki-67 expression and laryngeal cancer prognosis are yet 
inconsistently found in the literature.
The thirty patients in our study were aged between 
21 and 80 years (mean 56.2 years). The groups were di-
vided between subjects aged up to 50 and patients older 
than 50, and they were compared for cell markers p53 and 
Ki-67. The younger group had the same number of positive 
and negative cases, while in the older group the number 
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of positive cases was higher for both markers (61.5% for 
p53 and 80.8% for Ki-67). These results indicate that older 
patients have higher tumor proliferation rate and thus more 
aggressive disease.
The association between p53 and lymph node me-
tastasis was not proven, showing the equilibrium between 
marker expression and lymph node involvement (60% 
of the tumors were positive for p53, for both metastatic 
and non-metastatic disease). It failed to reveal statistical 
significance between groups.
Calli et al.12 investigated p53 and Ki-67 expression 
through immunohistochemistry in 37 patients diagnosed 
with laryngeal epidermoid carcinoma and found positive 
results in 83.8% of the cases for Ki-67 and 40% for p53, 
a statistically non-significant finding. Cruz et al.13 looked 
into 55 cases of oral cavity epidermoid carcinoma and 
reported positive results for p53 in 64% of the cases using 
a cut point of 25% of stained tumor cells. Kropveld et al.14 
analyzed 25 patients and used immunohistochemistry 
and PCR to detect p53 mutations. They found association 
between p53 mutation and carcinoma in 100% of the 
cases using both methods and in 96% of the cases using 
immunohistochemistry alone, using however a cut point 
of 50% of stained tumor cells. Rozemuller et al.15 looked 
at 50 carcinoma patients and used PCR to associate head 
and neck epidermoid carcinoma to p53 expression in 95% 
of the cases.
Our findings are not fully in agreement with the 
literature. This is probably due to the fact that the authors 
did not choose only tumors in the larynx, but in the who-
le head and neck region. Bosch et al.16 reported that the 
prevalence of p53 alterations (mutation, expression, and 
expression loss) is significantly higher in hypopharyngeal 
tumors than in other sites.
Antibody p53 was positive in 50% of the cases in 
our study. Seventy percent of them were high histologi-
cal grade tumors, and 60% had neck metastasis, possibly 
indicating that p53 immunohistochemical expression in 
epidermoid carcinoma patients is related to poor prognosis 
(high histological grade and regional metastasis).
Similarly to our study, Luo et al.17 investigated p53 
expression through immunohistochemistry tests in 76 pa-
tients and failed to find statistically significant correlations 
between gender, age, and disease staging (pT), while 
associations with histological grades (I, II, and III) were 
statistically significant. From these findings the authors su-
ggest that p53 expression present in early carcinomas may 
have important prognostic value. Another study supportive 
of this idea is the one published by Zhou et al.18, as p53 
expression was found in 0%, 31%, and 52% of cases of 
epithelial hyperplasia without atypia, epithelial hyperplasia 
with atypia, and laryngeal epidermoid carcinoma respecti-
vely. This same study reports p53 expression rates of 62%, 
76%, and 15% in well-differentiated carcinomas, modera-
tely differentiated carcinomas, and poorly differentiated 
carcinomas respectively. The authors concluded that p53 
expression is part of tumor pathogenesis and growth.
Seventy-six percent of the epidermoid carcinomas 
in our study presented immunohistochemical expression 
for Ki-67. Ki-67 expression was evident in 73.3% of the 
patients with metastatic lymph nodes and in 75% of high 
grade tumors. This suggests that Ki-67 may be related to 
poor prognosis factors (regional lymph node metastasis 
and high histological grade) in laryngeal epidermoid 
carcinoma cases (p>0.05). Liu et al.19 looked at 80 preo-
perative biopsies of patients histologically diagnosed with 
head and neck epidermoid carcinoma through immuno-
histochemistry for Ki-67 and correlated these findings 
to postoperative specimens, concluding that Ki-67 has a 
statistically significant predictive value to discern metastatic 
and non-metastatic carcinomas. Sun et al.20 analyzed 32 
cases of laryngeal epidermoid carcinoma and correlated 
their findings to Ki-67, T disease stage, and presence of 
metastatic lymph nodes to conclude that Ki-67 is statisti-
cally related to present tumor and poor prognosis.
The literature also support the hypothesis that Ki-67 
is associated with worse progress of laryngeal epidermoid 
carcinomas. Mirza et al.21 studied 80 patients histologically 
diagnosed with laryngeal mucosal dysplasia and performed 
immunohistochemistry tests for Ki-67. Ki-67 expression 
was categorized in terms of intensity in a scale from 0 to 
4. The patients were followed and twenty of them evolved 
to malignant carcinoma. The authors concluded that Ki-67 
at maximal expression levels (scores 3 and 4) was highly 
specific (80%) for laryngeal epidermoid carcinoma.
In terms of disease staging, p53 expression in 
early tumors was found in 50% of the cases, while Ki-67 
expression was seen in 100% of the cases categorized as 
pT1 (n=4). In advanced disease ranging between stages 
pT2 and pT4 (n=26), p53 and Ki-67 expression was seen 
in 61.5% and 73.1% of the cases respectively. There was 
no statistically significant correlation between laryngeal 
carcinoma stage and immunohistochemical expression of 
the two analyzed antibodies.
CONCLUSION
Except for the group aged 50 and more, in which 
Ki-67 expression was significantly higher, no statistically 
significant differences were found between p53 and Ki-67 
expression and laryngeal epidermoid carcinoma.
The other prognostic factors (histological grade, 
lymph node involvement, and disease staging) require 
more research to thus increase the number of cases and 
studies based on DNA sequencing to verify the presence 
of mutations.
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